Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
复制标题
脱敏后与dupilumab和阿司匹林治疗联合治疗非甾体类抗炎药加重的呼吸道疾病。
DOI：
10.1111/cea.14348
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Laidlaw,TanyaM
中科院分区：
文献类型：
--
作者：
Buchheit,KathleenM;Hacker,Jonathan;Maurer,Rie;McGill,Alanna;Ryan,Tessa;Bensko,JillianC;Laidlaw,TanyaM
非甾体类抗炎药（NSAID）加重的呼吸道疾病（NSAIDERD）的特征是成人发作的哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）和对环氧合酶1抑制剂的呼吸道反应。NSAID ERD患者患有重度CRSwNP，伴致密组织嗜酸性粒细胞增多和活化肥大细胞。持续释放炎性介质，包括半胱氨酰白三烯（cysLT）和前列腺素（PG）D2，是NSAID-ERD的标志，并在放大呼吸道炎症和嗜酸性粒细胞增多中发挥作用。1阿司匹林脱敏后阿司匹林治疗（ATAD）是NSAID ERD患者的一种治疗方式，可改善上呼吸道和下呼吸道症状，减缓鼻息肉在内窥镜鼻窦手术后的复发。2 ATAD对NSAID-ERD患者具有特异性;每日高剂量阿司匹林对阿司匹林耐受的CRSwNP或哮喘患者没有益处。ATAD有效的机制可能部分是由于减少了炎性前列腺素，
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAIDERD) is characterized by adult-onset asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase 1 inhibitors. Patients with NSAIDERD have severe CRSwNP with dense tissue eosinophilia and activated mast cells. Ongoing release of inflammatory mediators, including cysteinyl leukotrienes (cysLTs) and prostaglandin (PG) D2, is a hallmark of NSAID-ERD and plays a role in amplifying respiratory tract inflammation and eosinophilia. 1Aspirin desensitization followed by aspirin therapy after desensitization (ATAD) is a therapeutic modality specific for patients with NSAID-ERD that improves upper and lower respiratory symptoms and slows nasal polyp recurrence following endoscopic sinus surgery. 2 ATAD is specific for patients with NSAID-ERD; high-dose daily aspirin provides no benefit for patients with aspirin-tolerant CRSwNP or asthma. The mechanisms by which ATAD is efficacious are likely due in-part to reduction in inflammatory prostaglandins